← Back to Clinical Trials
Recruiting NCT06493227

NCT06493227 Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06493227
Status Recruiting
Phase
Sponsor Saint Petersburg State University, Russia
Condition Thoracic Surgery
Study Type INTERVENTIONAL
Enrollment 1,373 participants
Start Date 2024-08-01
Primary Completion 2025-12-30

Trial Parameters

Condition Thoracic Surgery
Sponsor Saint Petersburg State University, Russia
Study Type INTERVENTIONAL
Phase N/A
Enrollment 1,373
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-08-01
Completion 2025-12-30
Interventions
No routine fibrinolysis inhibitors after surgeryRoutine fibrinolysis inhibitors after surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.

Eligibility Criteria

Inclusion Criteria: 1. A hospital that performs a minimum of 250 open heart interventions per year. 2. Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol). Exclusion Criteria: * Hospital does not meet inclusion criteria

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology